121 related articles for article (PubMed ID: 22820083)
1. Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients.
Andjelkovic T; Bankovic J; Milosevic Z; Stojsic J; Milinkovic V; Pesic M; Ruzdijic S; Tanic N
Cancer Biomark; 2011-2012; 10(6):277-86. PubMed ID: 22820083
[TBL] [Abstract][Full Text] [Related]
2. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
[TBL] [Abstract][Full Text] [Related]
3. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients.
Andjelkovic T; Bankovic J; Stojsic J; Milinkovic V; Podolski-Renic A; Ruzdijic S; Tanic N
Transl Res; 2011 Jan; 157(1):19-28. PubMed ID: 21146147
[TBL] [Abstract][Full Text] [Related]
4. Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome.
Dragoj M; Milosevic Z; Bankovic J; Dinic J; Pesic M; Tanic N; Stankovic T
Tumour Biol; 2015 Nov; 36(11):8773-80. PubMed ID: 26055143
[TBL] [Abstract][Full Text] [Related]
5. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south Indian population.
Sushma PS; Jamil K; Kumar PU; Satyanarayana U; Ramakrishna M; Triveni B
Tumour Biol; 2016 Jun; 37(6):7625-32. PubMed ID: 26687648
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the p16(ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum.
Chen JT; Chen YC; Wang YC; Tseng RC; Chen CY; Wang YC
Int J Cancer; 2002 Apr; 98(5):724-31. PubMed ID: 11920642
[TBL] [Abstract][Full Text] [Related]
7. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
8. Detection of p16 abnormalities in early-stage non-small cell lung cancer.
Niklinska W; Chyczewski L; Laudanski J; Chyczewska E; Niklinski J
Folia Histochem Cytobiol; 2001; 39 Suppl 2():30-2. PubMed ID: 11820617
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
[TBL] [Abstract][Full Text] [Related]
10. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.
Ota N; Kawakami K; Okuda T; Takehara A; Hiranuma C; Oyama K; Ota Y; Oda M; Watanabe G
Anticancer Res; 2006; 26(5B):3729-32. PubMed ID: 17094392
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.
Marsit CJ; Zheng S; Aldape K; Hinds PW; Nelson HH; Wiencke JK; Kelsey KT
Hum Pathol; 2005 Jul; 36(7):768-76. PubMed ID: 16084946
[TBL] [Abstract][Full Text] [Related]
13. Significance of
DE Jesus Oliveira Kato V; DE Abreu MC; DE Brito Kato AM; DE Souza LL; Pontes FSC; DE Castro Sant'anna C; GonÇalves A; Pontes HAR; Khayat AS; Burbano RMR
Anticancer Res; 2020 Nov; 40(11):6355-6366. PubMed ID: 33109573
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).
Zhang JG; Wang JJ; Zhao F; Liu Q; Jiang K; Yang GH
Clin Chim Acta; 2010 Jun; 411(11-12):846-52. PubMed ID: 20223231
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.
Yoshino M; Suzuki M; Tian L; Moriya Y; Hoshino H; Okamoto T; Yoshida S; Shibuya K; Yoshino I
Int J Oncol; 2009 Nov; 35(5):1201-9. PubMed ID: 19787276
[TBL] [Abstract][Full Text] [Related]
16. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
17. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.
Soria JC; Lee HY; Lee JI; Wang L; Issa JP; Kemp BL; Liu DD; Kurie JM; Mao L; Khuri FR
Clin Cancer Res; 2002 May; 8(5):1178-84. PubMed ID: 12006535
[TBL] [Abstract][Full Text] [Related]
18. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas.
Marchetti A; Buttitta F; Pellegrini S; Bertacca G; Chella A; Carnicelli V; Tognoni V; Filardo A; Angeletti CA; Bevilacqua G
J Pathol; 1997 Feb; 181(2):178-82. PubMed ID: 9120722
[TBL] [Abstract][Full Text] [Related]
19. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
[TBL] [Abstract][Full Text] [Related]
20. [Abnormality of p16 gene and its clinicopathological significance in non-small cell lung cancer].
Fu J; Zhang J; Zhang HW
Zhonghua Bing Li Xue Za Zhi; 2003 Apr; 32(2):133-6. PubMed ID: 12839675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
